Julian Thorkild Gordon

US Patent:

6391543, May 21, 2002

Filed:

Apr 23, 1998

Appl. No.:

09/065383

Inventors:

Maurice Cohen - Highland Park IL
Tracey L. Colpitts - Round Lake IL
Paula N. Friedman - Deerfield IL
Julian Gordon - Lake Bluff IL
Edward N. Granados - Vernon Hills IL
Steven C. Hodges - Buffalo Grove IL
Michael R. Klass - Libertyville IL
Jon D. Kratochvil - Kenosha WI
John C. Russell - Pleasant Prairie WI
Stephen D. Stroupe - Libertyville IL

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

C12Q 168

US Classification:

435 6, 4352402, 4353201, 536 231, 536 243, 536 2431, 536 2432, 536 2433

Abstract:

A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as PS118 and transcribed from prostate tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the prostate, such as prostate cancer. Also provided are antibodies which specifically bind to PS118-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific PS118 polypeptide, which molecules are useful for the therapeutic treatment of prostate diseases, tumors or metastases.

US Patent:

6465181, Oct 15, 2002

Filed:

Mar 25, 1999

Appl. No.:

09/276600

Inventors:

Maurice Cohen - Highland Park IL
Tracey L. Colpitts - Round Lake IL
Julian Gordon - Lake Bluff IL
Edward N. Granados - Vernon Hills IL
John C. Russell - Pleasant Prairie WI
Stephen D. Stroupe - Libertyville IL

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

C12Q 168

US Classification:

435 6, 435 912, 435 915, 536 221, 536 235, 536 2431, 536 2433

Abstract:

A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as PCIGF and transcribed from prostate tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the prostate, such as prostate cancer. Also provided are antibodies which specifically bind to PCIGF-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific PCIGF polypeptide, which molecules are useful for the therapeutic treatment of prostate diseases, tumors or metastases.

US Patent:

6534320, Mar 18, 2003

Filed:

Mar 23, 1998

Appl. No.:

09/046171

Inventors:

Patricia A. Billing - Gurnee IL
Julian Gordon - Lake Bluff IL

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

G01N 33559

US Classification:

436514, 436506, 436518, 436524, 436525, 435 792, 435 5

Abstract:

The present invention relates to improved specific binding assay methods, kits and devices utilizing chromatographically mobile specific binding reagents labelled with colloidal particles. Specific binding reagents labelled with colloidal particles such as gold and selenium may be subjected to rapid chromatographic solvent transport on chromatographic media by means of selected solvents and chromatographic transport facilitating agents. Further, impregnation of solid substrate materials with labile protein materials including colloidal particle and enzyme labelled reagents in the presence of meta-soluble proteins provides for the rapid resolubilization of such materials which have been dried onto such substrate materials.

US Patent:

6627414, Sep 30, 2003

Filed:

Mar 30, 1998

Appl. No.:

09/050516

Inventors:

Maurice Cohen - Highland Park IL
Tracey L. Colpitts - Round Lake IL
Paula N. Friedman - Deerfield IL
Julian Gordon - Lake Bluff IL
Edward N. Granados - Vernon Hills IL
Mark A. Hayden - Ingleside IL
Steven C. Hodges - Buffalo Grove IL
Michael R. Klass - Libertyville IL
Jon D. Kratochvil - Wildwood MO
John C. Russell - Pleasant Prairie WI
Stephen D. Stroupe - Libertyville IL

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

C12P 2106

US Classification:

435 691, 435 6, 4352523, 4353201, 435325, 536 235, 536 2431

Abstract:

A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as CS 198 and transcribed from GI tract tissue, is described. These sequences are useful for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the GI tract, such as GI tract cancer. Also provided are antibodies which specifically bind to CS 198-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific CS 198 polypeptide, which molecules are useful for the therapeutic treatment of GI tract diseases, tumors or metastases.

US Patent:

6660834, Dec 9, 2003

Filed:

Oct 23, 2002

Appl. No.:

10/278547

Inventors:

Maurice Cohen - Highland Park IL
Tracey L. Colpitts - Round Lake IL
Paula N. Friedman - Deerfield IL
Julian Gordon - Lake Bluff IL
Edward N. Granados - Vernon Hills IL
Mark A. Hayden - Ingleside IL
Steven C. Hodges - Buffalo Grove IL
Michael R. Klass - Libertyville IL
Jon D. Kratochvil - Wildwood MO
John C. Russell - Pleasant Prairie WI
Stephen D. Stroupe - Libertyville IL

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

C07K 1447

US Classification:

530324, 530350, 530828, 435810

Abstract:

A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as CS198 and transcribed from GI tract tissue, is described. These sequences are useful for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the GI tract, such as GI tract cancer. Also provided are antibodies which specifically bind to CS198-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific CS198 polypeptide, which molecules are useful for the therapeutic treatment of GI tract diseases, tumors or metastases.

US Patent:

6770435, Aug 3, 2004

Filed:

Nov 1, 1999

Appl. No.:

09/431384

Inventors:

Maurice Cohen - Highland Park IL
Tracey L. Colpitts - Round Lake IL
Paula N. Friedman - Deerfield IL
Julian Gordon - Lake Bluff IL
Edward N. Granados - Vernon Hills IL
Steven C. Hodges - Buffalo Grove IL
Michael R. Klass - Libertyville IL
Jon D. Kratochvil - Wildwood MO
John C. Russell - Pleasant Prairie WI
Christi P. Scheffel - Mundelein IL
Stephen D. Stroupe - Libertyville IL

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

C12Q 168

US Classification:

435 6, 435 724, 435 94, 536 231, 536 243, 436501, 436504

Abstract:

A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as BU101 and transcribed from breast tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the breast, such as breast cancer. Also provided are antibodies which specifically bind to BU101-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific BU101 polypeptide, which molecules are useful for the therapeutic treatment of breast diseases, tumors or metastases.

US Patent:

6867016, Mar 15, 2005

Filed:

Mar 31, 1998

Appl. No.:

09/052855

Inventors:

Maurice Cohen - Highland Park IL, US
Tracey L. Colpitts - Round Lake IL, US
Paula N. Friedman - Deerfield IL, US
Julian Gordon - Lake Bluff IL, US
Edward N. Granados - Vernon Hills IL, US
Mark A. Hayden - Ingleside IL, US
Steven C. Hodges - Buffalo Grove IL, US
Michael R. Klass - Libertyville IL, US
Jon D. Kratochvil - Wildwood MO, US
John C. Russell - Pleasant Prairie WI, US
Stephen D. Stroupe - Libertyville IL, US

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

C12N005/10
C12N015/00
C07H021/04

US Classification:

435 691, 4353201, 435325, 4352523, 43525411, 536 235

Abstract:

A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as CS141 and transcribed from GI tract tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the GI tract, such as GI tract cancer. Also provided are antibodies which specifically bind to CS141-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific CS141 polypeptide, which molecules are useful for the therapeutic treatment of GI tract diseases, tumors or metastases.

US Patent:

6890749, May 10, 2005

Filed:

May 15, 1998

Appl. No.:

09/080140

Inventors:

Maurice Cohen - Highland Park IL, US
Tracey L. Colpitts - Round Lake IL, US
Paula N. Friedman - Deerfield IL, US
Julian Gordon - Lake Bluff IL, US
Edward N. Granados - Vernon Hills IL, US
Steven C. Hodges - Buffalo Grove IL, US
Michael R. Klass - Libertyville IL, US
Jon D. Kratochvil - Wildwood MO, US
John C. Russell - Pleasant Prarie WI, US
Stephen D. Stroupe - Libertyville IL, US

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

C07H021/04
C12N015/63
C12N005/10
C12N001/21
C12N001/19

US Classification:

4353201, 4352523, 43525411, 435325, 536 235

Abstract:

A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as PS116 and transcribed from prostate tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the prostate, such as prostate cancer. Also provided are antibodies which specifically bind to PS116-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific PS116 polypeptide, which molecules are useful for the therapeutic treatment of prostate diseases, tumors or metastases.